Carl Zeiss Meditec's AI Ambitions Confront a Collapsing Margin

Carl Zeiss Meditec launches AI platform at ophthalmology conference as Q1 revenue falls 4.8% and EBITA plummets 77%. Stock down 34% YTD.

The launch of a new artificial intelligence platform at a major U.S. ophthalmology conference should be a celebratory moment for Carl Zeiss Meditec. Instead, the company's showcase in Washington coincides with one of its most severe financial downturns in recent memory. The stark contrast between technological promise and present-day performance defines the current investor dilemma.

On the operational front, the figures are stark. For the first quarter of the 2025/26 fiscal year, revenue declined to 467.0 million euros, down 4.8 percent from 490.5 million euros a year earlier. The collapse in profitability was even more dramatic. Earnings before interest, taxes, and amortization (EBITA) plummeted from 35.2 million euros to just 8.1 million euros, sending the corresponding margin into a tailspin from 7.2 percent to a wafer-thin 1.7 percent.

This fundamental weakness has been brutally reflected in the share price. Since the start of the year, the stock has shed approximately 34 percent of its value. It recently traded at 25.78 euros, having touched a 52-week low of 22.62 euros on March 23. Analyst sentiment has turned cautious in response. Goldman Sachs recently trimmed its price target from 36 to 31 euros, maintaining a "Neutral" rating. In a broader move, consensus earnings per share estimates for the fiscal years 2026 through 2028 have been revised downward by 22 to 29 percent.

Against this challenging backdrop, the company is pressing forward with its digital strategy at the ASCRS annual meeting. The commercial U.S. launch of ZEISS VisioGen is the centerpiece. This AI-powered platform integrates directly into eye clinic websites to capture patient inquiries and funnel them toward scheduled examinations for cataract, refractive, and premium procedures. A key differentiator from fully automated chatbots is its hybrid model: all AI-generated responses are reviewed by trained optometrists before being delivered to patients, a feature designed to ease regulatory acceptance in the sensitive medical field.

The product offensive is rounded out by the introduction of ZEISS Collaborative Care, a browser-based, cloud application for secure data sharing and streamlined patient referrals among eye care professionals. The company is also demonstrating its VISUMAX 800 and MEL 90 laser platforms for corneal refractive surgery on the conference floor.

One recent strategic bright spot is the completed acquisition of D.O.R.C., which strengthens Carl Zeiss Meditec's position in the growing market for vitreoretinal surgery. Industry forecasts suggest this segment could expand from $2.43 billion in 2024 to around $3.45 billion by 2030.

All eyes are now firmly fixed on May 12, 2026. The release of the half-year figures on that date is expected to provide an updated full-year outlook and concrete details on planned restructuring and cost-saving initiatives. Investors will scrutinize management's commentary on reprioritized research and development, the demand trajectory in the critical Chinese market, and the results of China's nationwide volume-based procurement tender for intraocular lenses. The effectiveness of the newly launched cost programs will be the ultimate test of whether a sustainable recovery is taking hold.